FDG PET and FES PET Predict PFS on Endocrine Therapy-Letter.

Mammatas, Lemonitsa H; van Helden, Erik J; Verheul, Henk M W; Menke-van der Houven van Oordt, Catharina W

Mammatas, Lemonitsa H; van Helden, Erik J; Verheul, Henk M W; Menke-van der Houven van Oordt, Catharina W.

Afiliação

Mammatas LH; VUmc Cancer Center Amsterdam, VU University Medical Center, Department of Medical Oncology, Amsterdam, the Netherlands.
van Helden EJ; VUmc Cancer Center Amsterdam, VU University Medical Center, Department of Medical Oncology, Amsterdam, the Netherlands.
Verheul HMW; VUmc Cancer Center Amsterdam, VU University Medical Center, Department of Medical Oncology, Amsterdam, the Netherlands.
Menke-van der Houven van Oordt CW; VUmc Cancer Center Amsterdam, VU University Medical Center, Department of Medical Oncology, Amsterdam, the Netherlands. c.menke@vumc.nl.

Clin Cancer Res ; 24(1): 248, 2018 01 01.

Article em En | MEDLINE | ID: mdl-29298807

Assuntos

Neoplasias da Mama; Fluordesoxiglucose F18; Humanos; Tomografia por Emissão de Pósitrons; Intervalo Livre de Progressão; Receptores de Estrogênio

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Fluordesoxiglucose F18 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google